Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Perlman syndrome is characterized principally by polyhydramnios, neonatal macrosomia, bilateral renal tumors (hamartomas with or without nephroblastomatosis), hypertrophy of the islets of Langerhans and facial dysmorphism.
Features include always present findings: Everted upper lip vermilion; and very common findings: Large for gestational age, Wide nasal bridge, Open mouth, and Global developmental delay and others. 61 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Head and neck | 8 | Tented upper lip vermilion, Everted upper lip vermilion, Long upper lip |
Brain and nerves | 6 | Global developmental delay, Depressed nasal bridge, Intellectual disability |
Kidneys and urinary system | 4 | Renal hamartoma, Nephrogenic rest, Nephroblastomatosis |
Digestive system | 4 | Hypoplasia of the abdominal wall musculature, Pancreatic islet-cell hyperplasia, Ascites |
Heart and blood vessels | 2 | Interrupted aortic arch, Abnormality of the cardiovascular system |
Growth and development | 2 | Growth abnormality, Tall stature |
Pregnancy and birth | 1 | Congenital diaphragmatic hernia |
Muscles | 1 | Low muscle tone (hypotonia) |
Eyes | 1 | Ptosis |
Bones and joints | 1 | Femoral hernia |
DIS3L2 encodes DIS3 like 3'-5' exoribonuclease 2 (885 aa). 3'-5'-exoribonuclease that specifically recognizes RNAs polyuridylated at their 3' end and mediates their degradation. Highest expression in Testis (19.9 TPM) and Thyroid (15.8 TPM).
Perlman syndrome is caused by mutations in the DIS3L2 gene on chromosome 2.
DIS3L2 is classified as a druggable target (Clinically Actionable category) with score 0.0.
Genetic testing for DIS3L2 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 1 always present feature, 18 very common features, 14 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Perlman syndrome.
3 publications have been identified in PubMed for Perlman syndrome. Research spans Review / Meta-Analysis (33%), Case Report / Case Series (33%), and Basic Science / Preclinical (33%).
Levy E (2026). [PMID: 42040973](https://pubmed.ncbi.nlm.nih.gov/42040973/). *Case Rep Genet*. [Case Report / Case Series]
Meyer AP (2025). [PMID: 40704758](https://pubmed.ncbi.nlm.nih.gov/40704758/). *Mol Genet Genomic Med*. [Review / Meta-Analysis]
D'Silva S (2025). [PMID: 40500755](https://pubmed.ncbi.nlm.nih.gov/40500755/). *Cell Commun Signal*. [Basic Science / Preclinical]
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 1:54 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Perlman syndrome